Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0THODD
ADC Name
WO2024230301A1 ADC-17
Synonyms
WO2024230301A1 ADC-17
   Click to Show/Hide
Organization
NOVACYTE THERAPEUTICS CO., LTD
Drug Status
Investigative
Drug-to-Antibody Ratio
7.45
Structure
Antibody Name
trastuzumab
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
Undisclosed
Therapeutic Target
Stimulator of interferon genes protein (STING1)
  Target Info 
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (IC50)Human PBMC 
0.152
nM
CVCL_0033
Breast adenocarcinoma
Half Maximal inhibitory Concentration (IC50)Human PBMC 
0.6929
nM
CVCL_1603
Gastric tubular adenocarcinoma
Half Maximal inhibitory Concentration (IC50)Human PBMC 
20.4961
nM
CVCL_0031
Invasive breast carcinoma
Half Maximal inhibitory Concentration (IC50)Human PBMC 
34.0772
nM
CVCL_2077
Breast ductal carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (IC50)Human PBMC 0.152 nM Positive HER2 expression (HER2 +++/++)
Method Description
After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (IC50)Human PBMC 0.6929 nM High HER2 expression (HER2+++; >300,000 HER2 molecules/cell)
Method Description
After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (IC50)Human PBMC 20.4961 nM Negative HER2 expression (HER2-)
Method Description
After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model Invasive breast carcinoma MCF-7 cells CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (IC50)Human PBMC 34.0772 nM Positive HER2 expression (HER2 +++/++)
Method Description
After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model Breast ductal carcinoma JIMT-1 cells CVCL_2077
References
Ref 1 An antibody-drug conjugate and its uses